Clinical Trial: The Role of ERBT Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk NMIBC

U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07907575) titled 'The Role of ERBT Plus Adjuvant Intravesical Induction and Maintenance Chemotherapy for Intermediate-Risk NMIBC' on Oct. 25.

Brief Summary: This is a prospective, multi-centre randomised trial comparing between ERBT plus 1-year of Ad-MMC, versus ERBT alone, in treating intermediate-risk NMIBC.

Study Start Date: Jan. 01, 2027

Study Type: INTERVENTIONAL

Condition: Bladder Cancer

Intervention: DRUG: ERBT and Adjuvant MMC Therapy

Subject will receive 1-year of Ad-MMC after ERBT

PROCEDURE: ERBT

Subject will undergo ERBT

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Chinese University of Hong Kong

Information provided by (Res...